CHMP Responsibilities
What does the CHMP do?
The CHMP (Committee for Medicinal Products for Human Use) is EMA's committee for human medicines. EMA says it "plays a vital role in the authorisation of medicines in the European Union", mainly by assessing applications under the centralised procedure.
What it does (from EMA's CHMP page):
- Centralised marketing authorisations: It is responsible for "conducting the initial assessment of EU-wide marketing authorisation applications."
- Post-authorisation changes: It is responsible for "assessing modifications or extensions ('variations') to an existing marketing authorisation." It also considers safety recommendations and advises on changes to a medicine's marketing status.
- Referrals: It "evaluates medicines authorised at national level referred to EMA for a harmonised position across the EU."
- Support for medicine development: It gives scientific advice to developers, prepares regulatory guidelines and works internationally on harmonising regulation.
How it decides: It makes a "comprehensive scientific evaluation of data" to judge whether a medicine meets "quality, safety and efficacy requirements" and has "a positive risk-benefit balance." An internal peer-review system checks the accuracy of its assessments.
Who sits on it: It "consists of scientific experts appointed by EU Member States" and "meets once a month." EMA publishes the agendas, minutes and meeting highlights.
Approach: This comes from EMA's official CHMP page. The EMA records I can search hold the CHMP's meeting highlights, agendas and minutes, but no description of what the committee does.
Source: EMA: Committee for Medicinal Products for Human Use (CHMP)
Does a positive CHMP opinion mean a medicine is approved?
No. A positive CHMP opinion is a recommendation, not an approval. In the centralised procedure, the opinion goes to the European Commission, which issues the legally binding decision that grants the marketing authorisation across the EU.
What EMA's meeting highlights say
- After a positive opinion, EMA says: "The CHMP opinion will now be sent to the European Commission, which will issue a legally binding decision across the EU." [1]
- Other highlights put it the same way: the opinions are forwarded to the Commission, "which will issue a final legally binding decision applicable in all EU Member States." [2][3]
The Commission's decision is not automatic. The highlights record cases where the Commission did not simply adopt the opinion:
- Lecanemab (Leqembi): After the CHMP adopted its opinion in November 2024, the Commission asked the committee to consider new safety information "and whether this may require an update of the opinion." [4]
- January 2018 meeting: The Commission "suspended its decision-making" over good manufacturing practice (GMP) concerns at the site making the active substance, and "referred the matter back to the CHMP." [5]
- Plitidepsin (Aplidin): This shows the reverse case for a negative opinion. On 28 June 2024 the Commission revoked its refusal of a marketing authorisation, then asked EMA to restart the re-examination of the CHMP's December 2017 negative opinion. [6]
In short, a medicine with a positive CHMP opinion is recommended for approval. It is authorised only once the Commission decision is adopted.
Approach: I searched EMA's CHMP meeting highlights for how they describe the step from opinion to Commission decision. The highlights describe that step but give no timeline for the Commission's decision.
Where can I find CHMP meeting outcomes?
EMA publishes CHMP meeting outcomes in three places: the meeting highlights (EMA news items), the minutes and the agendas. The highlights are the quickest way to see a meeting's opinions. The minutes are the formal record.
1. Meeting highlights: the headline outcomes
- EMA publishes these as news items on ema.europa.eu, one for each monthly plenary. They list the positive and negative opinions, re-examinations and other key outcomes. They also say that opinions go to the European Commission for its decision.
- The most recent ones I found are for 20-23 July 2026 [7] and 22-25 June 2026 [8].
- Example link: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2026
2. Minutes: the formal record of each procedure
- EMA publishes these as PDFs under ema.europa.eu/en/documents/minutes/. They record discussions and outcomes procedure by procedure.
- Recent examples are the minutes of 23-26 February 2026 [9] and 8-11 December 2025 [10].
- Some minutes also have a spreadsheet annex, for example the Annex to the 13-16 October 2025 CHMP minutes [11].
- Minutes appear some months after the meeting. The latest I found is February 2026, while the latest highlights are from July 2026.
- EMA also publishes separate minutes for its organisational meetings (ORGAM) and its procedural meetings (PROM), for example the PROM minutes for 3 November 2025 [12].
3. Agendas: what will be discussed
- EMA publishes these as PDFs under ema.europa.eu/en/documents/agenda/ before each meeting.
- Recent examples are the agenda for 20-23 July 2026 [13], the written procedure of 17-20 August 2026 [14] and the extraordinary meeting of 16 March 2026 [15].
The archive I can search goes back to the December 2009 highlights. I can look up the CHMP outcome for a particular medicine or meeting if you name it.
Approach: I searched EMA's CHMP meeting highlights, agendas and minutes. I did not search EMA's opinion summaries or EPARs for this answer.